Breaking News

Tweet TWEET

Response Genetics, Inc. Announces Contracts With Two Additional Blue Cross Blue Shield Plans

Response Genetics, Inc. Announces Contracts With Two Additional Blue Cross
Blue Shield Plans

LOS ANGELES, Dec. 18, 2013 (GLOBE NEWSWIRE) -- Response Genetics, Inc.
(Nasdaq:RGDX), a company focused on the development and sale of molecular
diagnostic tests that help determine a patient's response to cancer therapy,
today announced that it has signed agreements with two new Blue Cross Blue
Shield health plans.

Response Genetics' new Blue Cross Blue Shield contracts are with:

  *Blue Cross and Blue Shield of Minnesota
  *Blue Cross and Blue Shield of Nebraska

These partnerships mark another leap forward in Response Genetics' growing
managed care contracting program. With these additional agreements, Response
Genetics is now in-network with a total of eight Blue Cross Blue Shield health
plans.Among Response Genetics' other Blue Cross Blue Shield contracts are
Blue Cross and Blue Shield of Illinois, Blue Shield of California and
CareFirst BlueCross BlueShield (Maryland, Washington, DC and Northern
Virginia).

Response Genetics' molecular testing primarily focuses on patients suffering
from lung, colon, gastric and melanoma cancers. Response Genetics' menu of
genomic assays gives treating physicians actionable information on a patient's
tumor and which course of therapy will work best for that patient. Response
Genetics' participation with these Blues plans should improve plan members'
access to individually-tailored medicine.

About Response Genetics, Inc.

Response Genetics, Inc. (the "Company") is a CLIA-certified clinical
laboratory focused on the development and sale of molecular diagnostic testing
services for cancer.The Company's technologies enable extraction and analysis
of genetic information derived from tumor cells stored as formalin-fixed and
paraffin-embedded specimens.The Company's principal customers include
oncologists and pathologists.In addition to diagnostic testing services, the
Company generates revenue from the sale of its proprietary analytical
pharmacogenomic testing services of clinical trial specimens to the
pharmaceutical industry.The Company's headquarters is located in Los Angeles,
California.For more information, please visit www.responsegenetics.com.

About Blue Cross and Blue Shield of Minnesota

Blue Cross and Blue Shield of Minnesota (bluecrossmn.com), a not-for-profit
organization with headquarters in the St. Paul suburb of Eagan, was chartered
in 1933 as Minnesota's first health plan and continues to carry out its
charter mission today as a health company: to promote a wider, more economical
and timely availability of health services for the people of Minnesota. Blue
Cross and Blue Shield of Minnesota is an independent licensee of the Blue
Cross and Blue Shield Association.

About Blue Cross and Blue Shield of Nebraska

Blue Cross and Blue Shield of Nebraska ("BCBSNE") is a community-based,
member-owned health insurance company serving nearly 700,000 people. Since
1939, BCBSNE has been committed to protecting Nebraska families and delivering
the health and wellness solutions Nebraskans value most. Recent awards
include: Platinum Well Workplace Award from the Wellness Councils of America
and Best Places to Work in Omaha. Blue Cross and Blue Shield of Nebraska is an
independent licensee of the Blue Cross and Blue Shield Association.

Forward-Looking Statement Notice

Except for the historical information contained herein, this press release and
the statements of representatives of the Company related thereto contain or
may contain, among other things, certain forward-looking statements, within
the meaning of the Private Securities Litigation Reform Act of 1995.

Such forward-looking statements involve significant risks and
uncertainties.Such statements may include, without limitation, statements
with respect to the Company's plans, objectives, projections, expectations and
intentions, such as the ability of the Company, to provide clinical testing
services to the medical community, to continue to strengthen and expand its
sales force, to continue to build its digital pathology initiative, to attract
and retain qualified management, to continue to strengthen marketing
capabilities, to expand the suite of ResponseDX® products, to continue to
provide clinical trial support to pharmaceutical clients, to enter into new
collaborations with pharmaceutical clients, to enter into areas of companion
diagnostics, to continue to execute on its business strategy and operations,
to continue to analyze cancer samples and the potential for using the results
of this research to develop diagnostic tests for cancer, the usefulness of
genetic information to tailor treatment to patients, and other statements
identified by words such as "project," "may," "could," "would," "should,"
"believe," "expect," "anticipate," "estimate," "intend," "plan" or similar
expressions.

These statements are based upon the current beliefs and expectations of the
Company's management and are subject to significant risks and uncertainties,
including those detailed in the Company's filings with the Securities and
Exchange Commission.Actual results, including, without limitation, actual
sales results, if any, or the application of funds, may differ from those set
forth in the forward-looking statements.These forward-looking statements
involve certain risks and uncertainties that are subject to change based on
various factors (many of which are beyond the Company's control).The Company
undertakes no obligation to publicly update forward-looking statements,
whether because of new information, future events or otherwise, except as
required by law.

CONTACT: Investor Relations Contact:
         Peter Rahmer
         Trout Group
         646-378-2973
        
         Company Contact:
         Thomas A. Bologna
         Chairman & Chief Executive Officer
         323-224-3900

Response Genetics Logo